DDInter1266 DDInter513
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Naproxen {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) is treated by {v} (Compound) Dexamethasone
Naproxen {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Naproxen {u} (Compound) causes {v} (Side Effect) Hyperglycaemia
Hyperglycaemia {u} (Side Effect) is caused by {v} (Compound) Dexamethasone
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Naproxen {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) is treated by {v} (Compound) Triamcinolone
Triamcinolone {u} (Compound) resembles {v} (Compound) Dexamethasone
Naproxen {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Dexamethasone
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is associated with {v} (Disease) brain cancer
brain cancer {u} (Disease) is palliated by {v} (Compound) Dexamethasone
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Triamcinolone
Triamcinolone {u} (Compound) resembles {v} (Compound) Dexamethasone
Naproxen {u} (Compound) causes {v} (Side Effect) Hyperglycaemia
Hyperglycaemia {u} (Side Effect) is caused by {v} (Compound) Fludrocortisone
Fludrocortisone {u} (Compound) resembles {v} (Compound) Dexamethasone
Naproxen (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Dexamethasone (Compound)
Naproxen (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Dexamethasone (Compound)
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Dexamethasone (Compound)
Naproxen (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Dexamethasone (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Naproxen (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Triamcinolone (Compound) and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Naproxen (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Hydrocortisone (Compound) and Hydrocortisone (Compound) resembles Dexamethasone (Compound)
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is associated with brain cancer (Disease) and brain cancer (Disease) is palliated by Dexamethasone (Compound)
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Triamcinolone (Compound) and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Naproxen (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Fludrocortisone (Compound) and Fludrocortisone (Compound) resembles Dexamethasone (Compound)